Fresh analysis reveals that patients who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Published data in a prominent health publication shows that while obese individuals can lose about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People using such drugs need to be aware of the danger of rapid weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight within about 18 months.
Analyzing Treatments
The analysis, which examined dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
The team note that people who shed pounds through lifestyle changes alone usually see a less rapid creep back—approximately 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors propose the mode of action of the drugs is key to understanding the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the body to produce less of its own natural GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, due to the likelihood of weight regain, the treatment might need to be long-term.
This opinion is supported by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Individuals who have stopped the medication explain a intense resurgence of appetite.
"It was like something activating and you become extremely hungry," recalled an individual.
This difficulty is worsened if patients have not adopted sustainable dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent tools for shedding pounds, they are not a permanent solution and lasting health benefits likely depends on ongoing behavioural changes.